Beneficial Ownership Report · SCHEDULE 13G
Electra Therapeutics, Inc.
ETRANASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Electra Therapeutics, Inc.
- Company CIK
- 0002088082
- Street
- 230 E Grand Avenue
- Street (continued)
- Suite S-100
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Statement details
- Security class
- Common Stock, par value $0.0001 per share
- Event date
- 09/21/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- LSP 7 Cooperatief U.A.
- Citizenship / organization
- P7
- Reporting person type
- OO
- Aggregate amount owned
- 3,795,281
- Percent of class
- 6.0
- Sole voting power
- 0
- Shared voting power
- 3,795,281
- Sole dispositive power
- 0
- Shared dispositive power
- 3,795,281
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- LSP 7 Management B.V.
- Citizenship / organization
- P7
- Reporting person type
- OO
- Aggregate amount owned
- 3,795,281
- Percent of class
- 6.0
- Sole voting power
- 0
- Shared voting power
- 3,795,281
- Sole dispositive power
- 0
- Shared dispositive power
- 3,795,281
- Aggregate excludes certain shares
- N
Item 1
Issuer
Electra Therapeutics, Inc.
Principal executive office address
230 E Grand Avenue, Suite S-100, South San Francisco, California 94080.
Item 2
Citizenship
Each of the Reporting Persons is organized under the laws of the Netherlands.
Filing person
Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of: LSP 7 Cooperatief U.A. ("LSP 7"); and LSP 7 Management B.V.
Principal business or residence address
The principal business address of each of the Reporting Persons is c/o EQT Life Sciences, Johannes Vermeerplein 9, 1071 DV Amsterdam, the Netherlands.
Item 3
Not applicable indication
Y
Item 4
Percent of class
6.0%
Amount beneficially owned
The ownership information presented herein represents beneficial ownership of Common Stock of the Issuer as of September 21, 2026, based on 62,766,955 shares of Common Stock outstanding as of September 21, 2026, as disclosed in the Issuer's prospectus supplement on Form 424B4 filed on September 18, 2026. LSP 7 is the record holder of the shares reported herein. LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Merijn Klaassen, Rene Kuijten and Joachim Rothe. As such, LSP 7 Management B.V., Merijn Klaassen, Rene Kuijten and Joachim Rothe may be deemed to beneficially own the shares of Common Stock held of record by LSP 7. Each of these individuals disclaims beneficial ownership of such shares.
Sole voting power
0
Shared voting power
3,795,281
Sole dispositive power
0
Shared dispositive power
3,795,281
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 1: Joint Filing Agreement.
Signature 1
- Reporting person
- LSP 7 Cooperatief U.A.
- Signed
- By: LSP 7 Management B.V., its managing director, /s/ Merijn Klaassen · By: LSP 7 Management B.V., its managing director, /s/ Rene Kuijten
- Title
- Merijn Klaassen, Managing Director · Rene Kuijten, Managing Director
- Date
- 09/28/2026 · 09/28/2026
Signature 2
- Reporting person
- LSP 7 Management B.V.
- Signed
- By: /s/ Merijn Klaassen · By: /s/ Rene Kuijten
- Title
- Merijn Klaassen, Managing Director · Rene Kuijten, Managing Director
- Date
- 09/28/2026 · 09/28/2026
Filed exhibits
- EX-99.1 ↗ck0000000000-ex99_1.pdf
Company context
We are a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. Our novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations, and increases upon activation to enable selective depletion of disease-driving cells while preserving normal immune function. By replacing broad immunosuppression with selective elimination of principal cells that drive disease, we believe our approach can do for immune-mediated diseases what precision oncology has done for cancer, transforming the treatment paradigm for patients. To our knowledge, we are the first company to advance this SIRP-targeted precision immune cell depletion approach into clinical development and demonstrate proof-of-concept in humans.